Comparing two methods of radioiodine treatment for thyroid cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial evaluates two different strategies for administering radioiodine treatment in patients with intermediate-risk differentiated thyroid cancer. One approach involves systematic administration of radioiodine, while the other relies on a post-operative assessment based on serum thyroglobulin levels and diagnostic RAI scintigraphy to guide treatment decisions. The study aims to determine which method is more effective in managing this patient population. Participants will be randomly assigned to one of the two treatment strategies following total thyroidectomy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subgroup of patients with differentiated thyroid cancer and intermediate-risk defined as follows according to TNM 2017:

  * Papillary thyroid cancer (PTC) without aggressive subtype, follicular thyroid cancer (FTC) (with \< 4 foci of vascular invasion) or Hürthle cell carcinoma (HCC)
  * T1b or T2 with minimal extra-thyroid extension into the perithyroidal soft tissues and/or pN1 with largest nodal dimension between 2 and 10 mm, without extra-capsular invasion and with a number of metastatic nodes ≤ 10
  * T1aN1 with largest nodal dimension between 2 and 10 mm, without extra-capsular invasion and with a number of metastatic nodes ≤ 10
* Patient treated by total thyroidectomy with macroscopically complete tumor resection (R0 or R1) ± neck dissection
* Total thyroidectomy performed within 6 to 14 10 weeks before randomization
* Patient with or without anti-thyroglobulin antibodies (TgAb)
* No known distant metastases
* Normal post-operative neck ultrasound (US) or if doubtful US, negative cytology and normal Tg value (\<10 ng/ml) in FNA washout fluid
* Post-operative LT4 treatment initiated at least 6 weeks before randomization
* Performance Status 0 or 1
* Patients aged 18 years or older
* Signed informed consent form
* Patient who agrees to be followed annually during 5 years
* Patient affiliated to the French social security system

Exclusion Criteria:

* • Patients with:

  * medullary or anaplastic thyroid cancer
  * or poorly differentiated carcinoma
  * or well differentiated FTC with at least more than 4 foci of vascular invasion
  * or PTC with aggressive variants (tall cell or columnar cell carcinoma, diffuse sclerosing papillary, hobnail variant)
  * NIFTP (Noninvasive follicular thyroid neoplasm with papillary-like nuclear features)

    • Low-risk or high-risk DTC patients according to ATA 2015, and intermediate-risk patients with extra-thyroid extension into the perithyroidal muscles (pT3b according to pTNM 2017), and/or pN1 with nodal largest dimension \>10 mm or with extra-capsular invasion or more than 10 metastatic nodes. This excludes the following patients:
  * All pT1a, pT3 or pT4
  * pT1aN0/x with or without minimal extra-thyroid extension
  * pT1bN0/x, pT2N0/Nx without minimal extra-thyroid extension
  * pT1aN1 or pT1bN1 or pT2N1 without extra-thyroid extension and with nodal largest dimension \<2mm
  * pT1aN1 or pT1bN1 or pT2N1 without extra-thyroid extension and with nodal largest dimension \>10mm
  * pT2N0/Nx without extra-thyroid extension
  * pT2N1 without extra-thyroid extension and with nodal largest dimension \<2mm
  * pT2N1 without extra-thyroid extension and with nodal largest dimension \>10mm
  * Surgery considered as macroscopically incomplete (R2)

    * Patients who have undergone lobectomy only
    * Post-operative neck US with metastatic lymph-nodes confirmed by cytology or by increased Tg (\>10 ng/ml) in FNA washout fluid
    * Drugs affecting thyroid function including iodinated contrast agents in the 6 weeks prior to randomization. Amiodarone should have been stopped at least 1 year before randomization.
    * Previous RAI treatment for thyroid cancer
    * Pregnant or lactating women
    * Any associated geographical, social or psychopathological condition that could compromise the patient's ability to participate in the study
    * Patient deprived of liberty or placed under the authority of a tutor
    * History of malignancy in the past 3 years, except skin cancer excluding melanoma, carcinoma in situ of the cervix. Any other solid tumor or lymphoma (without bone marrow involvement) must have been treated and not have shown signs of recurrence for at least 3 years

Where it's running

• Chu Angers
  Angers, France Recruiting
• Institu de Cancérologie de l'Ouest - Site Angers
  Angers, France Recruiting
• Bergonié
  Bordeaux, France Recruiting
• Hôpital saint-André
  Bordeaux, France Recruiting
• Chu Brest
  Brest, France Recruiting
• Centre Francois Baclesse
  Caen, France Recruiting

Study contacts

• Study coordinator: Renaud CIAPPUCCINI, MD
• Email: r.ciappuccini@baclesse.unicancer.fr
• Phone: (33)231455050

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MRG003 added to ongoing treatment after progression in EGFR-positive advanced thyroid cancer

  In this study, researchers test whether adding MRG003 to a patient’s current thyroid cancer treatment can shrink tumors for those whose cancer initially responded but later progressed.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07874321

• Selective coverage radiotherapy vs. full coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer

  This trial tests whether covering only the tumor-affected area with radiation is as effective as full-area coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer, while aiming to reduce side effects and improve quality of life.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07777536

• Trop-2 Targeted PET/CT for Recurrent and Metastatic Thyroid Cancer

  This study tests whether a Trop-2 targeted PET/CT scan can better detect recurrent or metastatic thyroid cancer in adults than another PET/CT scan (FAPI).

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07753499

• WeChat-supported neck exercises after thyroidectomy

  A telehealth program using a WeChat mini program tests if guided neck exercises after thyroid surgery help early recovery and quality of life.

  Recruiting Shanghai 6th People's Hospital · Shanghai, Shanghai Municipality · NCT07707401

• Pralsetinib Drug Interaction Study in RET Fusion/MUTATION Positive Solid Tumors

  This trial tests whether pralsetinib changes how the body processes certain medicines in adults with RET fusion- or mutation-positive advanced solid tumors.

  Recruiting at 2 sites Phase 4 Rigel Pharmaceuticals · Logroño, La Rioja and 1 other locations · NCT07704658

• AI chatbot to guide thyroid cancer patients through perioperative education

  A new AI chatbot is being tested to see if it helps thyroid cancer patients better prepare for discharge, recover well, and stay engaged in their care compared with traditional education.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07634978

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.